{
  "count": 5,
  "data": [
    {
      "campname": "Patient’s First Email", 
      "link":"#!/emailoutreachdetail",
      "senton": "Sent on Sun, Sep 08, 2016 9:00 am",
      "subscription": { "value": "18,656" },
      "unsubscription": { "value": 242 },
      "clicks": { "value": "4,664" },
      "trialname": "Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)"
      
    },
    {
      "campname": "Physician Campaign", 
      "link":"#!/emailoutreachdetail",
      "senton": "Sent on Mon, Aug 22, 2016 10:00 am",
      "subscription": { "value": 456 },
      "unsubscription": { "value": 10 },
      "clicks": { "value": 5 },
      "trialname": "Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)"
      
    },
    {
      "campname": "Campaign A/B Testing", 
      "link":"#!/campaignab_testing",
      "senton": "Sent on Sun, Sept 15, 2016 9:00 am",
      "subscription": { "value": "18,656" },
      "unsubscription": { "value": 643 },
      "clicks": { "value": "13,146" },
      "trialname": "Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)"
      
    },
    {
      "campname": "Patient outbound email", 
      "link":"#!/emailoutreachdetail",
      "senton": "Sent on Sun, May 08, 2016 9:00 am",
      "subscription": { "value": 201 },
      "unsubscription": { "value": 56 },
      "clicks": { "value": 2 },
      "trialname": "Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma"
      
    },
    {
      "campname": "Campaign - Atlanta", 
      "link":"#!/emailoutreachdetail",
      "senton": "Sent on Sun, May 08, 2016 9:00 am",
      "subscription": { "value": 321 },
      "unsubscription": { "value": 101 },
      "clicks": { "value": 4 },
      "trialname": "Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)"
      
    },
    {
      "campname": "Demographic target", 
      "link":"#!/emailoutreachdetail",
      "senton": "Sent on Sun, May 08, 2016 9:00 am",
      "subscription": { "value": 95 },
      "unsubscription": { "value": 21 },
      "clicks": { "value": 1 },
      "trialname": "AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer"
      
    },
    {
      "campname": "Patient outbound email", 
      "link":"#!/emailoutreachdetail",
      "senton": "Sent on Sun, May 08, 2016 9:00 am",
      "subscription": { "value": 159 },
      "unsubscription": { "value": 62 },
      "clicks": { "value": 2 },
      "trialname": "Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis"
      
    },
    {
      "campname": "Campaign - Atlanta", 
      "link":"#!/emailoutreachdetail",
      "senton": "Sent on Sun, May 08, 2016 9:00 am",
      "subscription": { "value":88 },
      "unsubscription": { "value": 18 },
      "clicks": { "value": 0 },
      "trialname": "Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)" 
      
    },
    {
      "campname": "Patient outbound email", 
      "link":"#!/emailoutreachdetail",
      "senton": "Sent on Sun, May 08, 2016 9:00 am",
      "subscription": { "value": 189 },
      "unsubscription": { "value": 45 },
      "clicks": { "value": 4 },
      "trialname": "Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)"
      
    },
    {
      "campname": "Campaign - Atlanta", 
      "link":"#!/emailoutreachdetail",
      "senton": "Sent on Sun, May 08, 2016 9:00 am",
      "subscription": { "value":88 },
      "unsubscription": { "value": 18 },
      "clicks": { "value": 0 },
      "trialname": "Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)" 
      
    }
  ]
}